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TO THE EDITOR
Venous ulcers represent the severe end
of the spectrum of chronic venous
disorders of the leg. Prevalence of
chronic venous ulceration increases
progressively with age, with a point
prevalence of approximately 1% in the
population over the age of 70 years
(Baker et al., 1991; Nelzen et al., 1994;
O’Brien et al., 2000). Primary risk
factors for venous ulcers are those for
the development of chronic venous
insufficiency, namely primary abnorm-
alities of the venous wall and valves
and secondary changes owing to pre-
vious venous thrombosis (Nicolaides,
2000).
Importantly, not all individuals with
venous insufficiency develop leg ulcers.
It is likely that a number of inherent
factors contribute to susceptibility, in-
cluding inherited genetic alterations.
Apart from the risk factors for chronic
venous insufficiency, increasing age
and female gender are the only other
established risk factors for the develop-
ment of venous leg ulcers (Graham
et al., 2003). Evidence for the role of
genetic predisposition is limited, but
the association of a single nucleotide
polymorphism (SNP) in the 30 untrans-
lated region of the fibroblast growth
factor receptor-2 (FGFR-2) gene with
venous leg ulceration has recently been
reported in this journal (Nagy et al.,
2005).
There is interest in the role of
inflammatory processes in the patho-
genesis of venous ulceration. We have
found that leg ulcer wound fluid levels
of the proinflammatory cytokines inter-
leukin-1 (IL-1) and tumor necrosis
factor alpha (TNFa) are much higher
than the levels found in wound fluid
from normal acute wounds (Baker and
Leaper, 2000), and decrease as ulcers
start to heal (Wallace and Stacey,
1998). Other studies have shown that
levels of matrix metalloproteinases
(MMPs), including MMP-3 (Vaalamo
et al., 1996) and MMP-2 (Wysocki
et al., 1993), are elevated in venous
ulcers. We hypothesized that functional
polymorphisms in proinflammatory cy-
tokine and MMP genes, or genes
involved in their regulation, may be
risk factors for the development of
venous leg ulcers.
We conducted a case–control study
comparing the frequency of gene poly-
morphisms in 181 Caucasian patients
with a history of confirmed venous leg
ulceration and 181 age- and gender-
matched healthy controls, also of Cau-
casian background. Control subjects
were excluded if they had abnormal
venous function (venous refilling
time less than 25 seconds on photo-
plethysmography). Subjects were ex-
cluded if they had type I diabetes or
rheumatoid arthritis. All subjects pro-
vided their written informed consent.
The study was approved by the Fre-
mantle Hospital Human Research
Ethics Committee and was conducted
according to the Declaration of Helsin-
ki Principles.
Polymorphisms in genes playing a
role in normal wound healing or in the
regulation of inflammatory processes
were selected (Table 1). They included
a G-A polymorphism in the promoter
of the TNFA gene (TNFA-308) located
in the central region of the major
histocompatibility complex (MHC).
This is a region of strong linkage
disequilibrium, where large conserved
blocks of genes are maintained in
particular arrangements of alleles
known as ancestral haplotypes. Ap-
proximately 70% of Caucasian indivi-
duals carrying the TNFA308A allele
also have part or all of the 8.1 ancestral
haplotype (HLA-A1, B8, DR3, and
DQ2) associated with numerous im-
munopathological disorders, including
type I diabetes and rheumatoid arthritis
(Price et al., 1999). We therefore also
examined a polymorphism located in
intron 10 of the HLA-B-associated
transcript-1 (BAT-1) gene used as a
marker of this haplotype (Price et al.,
2002). Polymorphisms were genotyped
using polymerase chain reaction (PCR)-
based methods (Table 1). The estima-
tion of relative risk of venous ulceration
is based on logistic regression analysis.
Crude and adjusted (for age and gender)
odds ratios (OR) are reported with 95%
confidence intervals (95% CI). Analyses
were performed with the statistical
package SPSS for Windows version
11.5.0.
Carriage of the TNFA-308A allele
was a significant risk factor for venous
ulceration (adjusted OR 2.48; 95% CI
1.54–3.97; P¼ 0.000155) (Table 2).
Although not statistically significant,
the risk appeared to be higher for
TNFA308AA homozygotes (adjusted
OR 8.08; 95% CI 0.95–68.53) than
TNFA308GA heterozygotes (adjusted
OR 2.32; 95% CI 1.44–3.76) compared
to the wild type (GG) (Table 3). The
marker in intron 10 of the BAT1 gene (C
insertion) was also a significant risk
factor (adjusted OR 2.00; 95% CI
1.16–3.44) (Table 2). Cases and controls
were evenly matched for age and
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Abbreviations: BAT1, HLA-B-associated transcript 1; CI, confidence interval; FGFR, fibroblast growth
factor receptor; F-SSCP, fluorescence-based single strand conformational polymorphism; HLA, human
leukocyte antigen complex; IL-1, interleukin-1; IL-1RN, interleukin-1 receptor antagonist; MHC, major
histocompatibility complex; MMP, matrix metalloproteinase; OR, odds ratio; PAI1, plasminogen
activator inhibitor 1; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; TNFa,
tumor necrosis factor alpha; TNFA, tumor necrosis factor alpha (gene)
gender, and adjustment of the odds
ratios for these covariates had little
effect. Polymorphisms in the MMP2,
MMP3, PAI1, and IL-1RN genes were
not associated with ulceration in this
population. All genotypes were in
Hardy–Weinberg equilibrium.
This study focused on genetic asso-
ciations to test the hypotheses about
causal pathways for venous leg ulcera-
tion. The use of case–control studies to
identify disease-associated genes car-
ries a high risk of false-positive findings,
and we calculated the false-positive
report probability (FPRP) using an ap-
proach recently described by Wa-
cholder et al. (2004). For carriage of
TNFA308A, the FPRP varied from
0.007 to 0.076 for prior probabilities of
the hypothesis ranging from 0.1 (high)
to 0.01 (moderate), well below the 0.2
level proposed by Wacholder et al.
(2004) as stringent. For the BAT1 intron
10 marker (C insertion), the FPRP was
also below 0.2 (0.181) using a prior
probability of 0.1. This analysis suggests
that the TNFA-308A association is
Table 1. Genotyping methods and disease association references
Gene (polymorphism) Primer/probe sequences Genotyping method AT1 (1C) Disease associations
TNFA (308 G/A) F: 50-CCTGCATCCTGTCTGGAAGT Fluorescence-based single strand
conformation polymorphism analysis




Designed using Primer3 software (Rozen
and Skaletsky, 2000)
MMP3 (1171 5A/6A) F: 50-TGGTTCTCCATTCCTTTGATG F-SSCP analysis (Grieu et al., 2004) 55 Ye (2000)
R: 50-AATTCACATCACTGCCACCA
Designed using Primer3 software (Rozen
and Skaletsky, 2000)
PAI1 (675 4G/5G) F: 50-CTCAGGGGCACAGAGAGAGT F-SSCP analysis (Grieu et al., 2004) 55 Nordt et al. (2001)
R: 50-TCTTGGTCTTTCCCTCATCC
Designed using Primer3 software (Rozen
and Skaletsky, 2000)
IL-1RN intron 2 (variable
number of tandem
repeats: VNTR)
F: 50-CTCAGCAACACTCCTAT Agarose gel fragment size analysis
(3% agarose)
50 Witkin et al. (2002)
R: 50-TCCTGGTCTGCAGGTAA
(Tarlow et al., 1993)
MMP2 (1306 C/T) F: 50-GCCATTGTCAATGTTCCCTAAAACA TaqMans SNP Genotyping Assay
(Applied Biosystems, Foster City, CA)






BAT1 intron 10 (/C) F: 50-CTACCGTGTCTGTTCAACTGAGAA TaqMans SNP Genotyping Assay
(Applied Biosystems, Foster City, CA)






BAT1=HLA-B-associated transcript 1; IL-1RN=interleukin-1 receptor antagonist; MMP=matrix metalloproteinase; PAI1=plasminogen activator inhibitor 1;
TNFA=tumor necrosis factora (gene).
1Annealing temperature.
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particularly ‘‘noteworthy’’, with a low
risk of being a false-positive finding.
The approximate two-fold increase
in risk of ulceration seen in carriers of
the TNFA308A allele or the BAT1
marker of the 8.1 MHC ancestral
haplotype is likely to be biologically
significant. The association found here
was independent of the presence of
type I diabetes or rheumatoid arthritis.
The TNFA308A polymorphism has
been shown to increase TNFa protein
levels in some studies (Hajeer and
Hutchinson, 2001). We have inferred
that the 8.1 ancestral haplotype of the
MHC was carried by 66% of the
TNFA308A individuals in the study
through the BAT1 marker (data not
shown). Several candidate genes in the
MHC region have the potential to
modulate immune or inflammatory
responses. It is not possible to conclude
from this data whether the association
with venous ulceration is owing to the
direct influence of the TNFA308A
allele or owing to linkage disequili-
brium with another polymorphism in
this region of the MHC. The sample size
of the study was too small to allow
subgroup analysis.
A larger population-based study
looking at an increased number of
genetic markers is required to identify
whether the causal allele for increased
risk of venous ulceration in this region
of the MHC is TNFA308A. Future
investigations on the effect of TNFA
genotype on local TNFa mRNA and
protein levels in leg ulcers will help to
determine if the TNFA308A poly-
morphism has a role in the disease
process. These results support the hy-
Table 2. Results of genotype analysis




Odds ratio (95% CI)
Significance
Adjusted OR3 (95% CI)
Significance
TNFA (308 G/A) 43.1 22.6 2.59 (1.64–4.08) 2.48 (1.54–3.97)
P=0.00003 P=0.000155
BAT1 (/C in intron 10) 28.8 16.3 2.08 (1.23–3.52) 2.00 (1.16–3.44)
P=0.0055 P=0.012
MMP3 (1171 5A/6A) 73.5 72.4 1.00 1.11
(0.62–1.60) (0.68–1.80)
NS NS
MMP2 (1306 C/T) 93.2 92.9 1.08 (0.46–2.51) 1.17 (0.47–2.92)
NS NS
PAI1 (–675 4G/5G) 82.3 79.5 1.20 (0.71–2.02) 1.11 (0.64–1.92)
NS NS
IL-1RN (variable number of tandem repeats
in intron 2. IL-1RN*2 contains two repeats)
49.4 44 1.24 (0.81–1.91) 1.31 (0.84–2.05)
NS NS
BAT1=HLA-B-associated transcript 1; CI=confidence interval; IL-1RN=interleukin-1 receptor antagonist; MMP=matrix metalloproteinase; OR=odds ratio;
PAI1=plasminogen activator inhibitor 1; TNFA=tumor necrosis factora (gene).
1Carriers include both heterozygotes and homozygotes.
2Bold type indicates postulated high-risk allele.
3Adjusted for age and gender. NS=not significant (P40.05).
Table 3. TNFA308 genotype results
Frequency1
TNFA308 genotype2 Ulcer patients Controls Adjusted OR (95% CI)3 Significance
GG 103 (56.9) 140 (77.3) Reference
GA 71 (39.2) 40 (22.1) 2.32 (1.44–3.76) P=0.001
AA 7 (3.9) 1 (0.06) 8.08 (0.95–68.5) P=0.055
CI=confidence interval; OR=odds ratio; TNFA=tumor necrosis factora (gene).
1Data show numbers of subjects with percentages in parentheses.
2Bold type indicates postulated high-risk allele.
3Adjusted for age and gender.
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pothesis that chronic inflammation is an
important part of the pathophysiology
of venous ulceration. If future results
provide evidence that TNFA308A is a
critical allele responsible for increased
risk, specific treatments directed at
reducing TNFa levels may be appro-
priate. In addition, the TNFA308A
allele may be a useful marker to identify
patients at high risk of ulceration
among those who are already at sig-
nificant risk: in particular, patients with
a history of deep vein thrombosis.
ACKNOWLEDGMENTS
The work was carried out at the School of Surgery
and Pathology, The University of Western Aus-
tralia, Fremantle Hospital, Fremantle, Western
Australia, Australia. This study was funded by
grants from the Fremantle Hospital Medical
Research Foundation and the Australian National
Health and Medical Research Council (Project
Grant No. 353645). These funding sources had no
additional role in the study. We thank the
following individuals for their direct contri-
butions to the study: Fabienne Grieu, Barry
Iacopetta, Patricia Price, Linda Smallwood, Ri-
chard Allcock, Michelle England, and those
members of the public who took part in the study.
Hilary J. Wallace1, Yvonne K.
Vandongen1 and Michael C. Stacey1
1School of Surgery and Pathology, The Uni-
versity of Western Australia, Fremantle Hospi-
tal, Fremantle, Western Australia, Australia.
E-mail: hilary@cyllene.uwa.edu.au
REFERENCES
Baker EA, Leaper DJ (2000) Proteinases, their
inhibitors, and cytokine profiles in acute
wound fluid. Wound Rep Reg 8:392–8
Baker SR, Stacey MC, Jopp-McKay A, Hoskin SE,
Thompson PJ (1991) Epidemiology of chronic
venous ulcers. Br J Surg 78:864–7
Graham ID, Harrison MB, Nelson EA, Lorimer K,
Fisher A (2003) Prevalence of lower-limb
ulceration: a systematic review of prevalence
studies. Adv Skin Wound Care 16:305–16
Grieu F, Joseph D, Norman P, Iacopetta B (2004)
Development of a rapid genotyping method
for single nucleotide polymorphisms and its
application in cancer studies. Oncol Rep
11:510–4
Hajeer AH, Hutchinson IV (2001) Influence of
TNFa gene polymorphisms on TNFa produc-
tion and disease. Hum Immunol 62:1191–9
Nagy J, Szolnoky G, Szabad G, Bata-Cso¨rgo Z,
Dobozy A, Keme´ny L et al. (2005) Single
nucleotide polymorphisms of the fibroblast
growth factor receptor 2 gene in patients with
chronic venous insufficiency with leg ulcer.
J Investig Dermatol 124:1085–8
Nelzen O, Bergqvist D, Lindhagen A (1994)
Venous and non-venous leg ulcers: clinical
history and appearance in a population
study. Br J Surg 81:182–7
Nicolaides AN (2000) Investigation of chronic
venous insufficiency. Circulation 102:
e126–63
Nordt TK, Lohrmann J, Bode C (2001) Regulation
of PAI-1 expression by genetic polymorph-
isms – impact on atherogenesis. Thromb Res
103:S1–5
O’Brien JF, Grace PA, Perry IJ, Burke PE (2000)
Prevalence and aetiology of leg ulcers in
Ireland. Ir J Med Sci 169:110–2
Price P, Bolitho P, Jaye A, Glasson M, Yindom LM,
Sirugo G et al. (2002) A Gambian TNF
haplotype matches the European HLA-
A1,B8,DR3 and Chinese HLA-A33,B58,DR3
haplotypes. Tissue Antigens 62:72–5
Price P, Witt C, Allcock R, Sayer D, Garlepp M,
Kok CC et al. (1999) The genetic basis for the
association of the 8.1 ancestral haplotype
(A1, B8, DR3) with multiple immuno-
pathological disorders. Immunol Rev 167:
257–74
Price SJ, Greaves DR, Watkins H (2001) Identifi-
cation of novel, functional genetic variants in
the human matrix metalloproteinase-2 gene.
J Biol Chem 276:7549–58
Rozen S, Skaletsky H (2000) Primer3 on the
WWW for general users and for biologist
programmers. In: Bioinformatics methods
and protocols. (Krawetz S, Misener S, eds),
Totowa, NJ: Humana Press, 365–86
Tarlow JK, Blakemore AI, Lennard A, Solari R,
Hughes HN, Steinkasserer A et al. (1993)
Polymorphism in human IL-1 receptor an-
tagonist gene intron 2 is caused by variable
numbers of an 86-bp tandem repeat. Hum
Genet 91:403–4
Vaalamo M, Weckroth M, Puolakkainen P, Kere J,
Saarinen P, Lauharanta J et al. (1996) Patterns
of matrix metalloproteinase and TIMP-1
expression in chronic and normally healing
human cutaneous wounds. Br J Dermatol
135:52–9
Wacholder A, Chanock S, Garcia-Closas M, El
ghormli L, Rothman N (2004) Assessing the
probability that a positive report is false: an
approach for molecular epidemiology stu-
dies. J Natl Cancer Inst 96:434–42
Wallace HJ, Stacey MC (1998) Levels of tumour
necrosis factor-alpha (TNF-alpha) and solu-
ble TNF receptors in chronic venous leg
ulcers – correlations to healing status.
J Investig Dermatol 110:292–6
Witkin SS, Gerber S, Ledger WJ (2002) Influence
of interleukin-1 receptor antagonist gene
polymorphism on disease. Clin Infect Dis
34:204–9
Wysocki AB, Staiano-Coico L, Grinnell F (1993)
Wound fluid from chronic leg ulcers contains
elevated levels of metalloproteinases MMP-2
and MMP-9. J Investig Dermatol 101:64–8
Ye S (2000) Polymorphism in matrix metallopro-
teinase gene promoters: implication in reg-
ulation of gene expression and susceptibility
of various diseases. Matrix Biol 19:623–9
926 Journal of Investigative Dermatology (2006), Volume 126
HJ Wallace et al.
TNFa Gene Polymorphism and Venous Leg Ulceration
